The emergence of mephedrone along with other artificial cathinones has offered challenges for lawmakers and regulatory organizations tasked with controlling the proliferation of recent psychoactive substances. The dynamic character of artificial drug manufacturing, coupled with the power of chemists to switch molecular structures to evade lawful li